COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00863889
Recruitment Status : Withdrawn
First Posted : March 18, 2009
Last Update Posted : September 23, 2013
Information provided by (Responsible Party):
Thomas L Bradbury, MD, Emory University

Brief Summary:
The objective of this study is to conduct a randomized, single-blinded placebo controlled trial comparing two modalities for the treatment of pain and mobility associated with trochanteric bursitis: (1) injection of glucocorticosteroid and local anesthetic, (2) injection of local anesthetic. We hope to determine whether steroid injections provide a statistically significant improvement in pain symptoms and hip mobility in subjects with trochanteric bursitis, as compared to an injection of local anesthetic. Our null hypothesis is that no statistically significant difference exists between the two treatment modalities.

Condition or disease Intervention/treatment Phase
Bursitis Drug: Depomedrol injection Drug: Lidocaine, Marcaine Phase 4

Detailed Description:

Trochanteric bursitis is an inflammation of the bursal sac overlying the greater trochanter of the femur. The etiology of this disease is unknown, but it is clinically characterized by chronic aching pain over the lateral aspect of the hip, which can be exacerbated by certain movements such as external rotation and abduction (2). In order to objectively determine the level of pain and mobility associated with trochanteric bursitis, some orthopaedic surgeons use scoring systems (a qualitative and quantitative scoring test) to assess patients (4).

In our practice, trochanteric bursitis has been treated by injection of glucocorticosteroids (steroids) combined with local anesthetic at the site of the greater trochanter (1). Additionally, it has been found that increasing steroid dosage provides a greater level of relief (3). Although steroids are usually an effective treatment, no studies to date have compared steroid injections for relief of trochanteric bursitis pain and mobility versus a placebo injection or local anesthetic injection alone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome: A Randomized Controlled Trial
Study Start Date : March 2009
Actual Primary Completion Date : February 2010
Actual Study Completion Date : February 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bursitis

Arm Intervention/treatment
Experimental: 1
1cc Depomedrol, 4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
Drug: Depomedrol injection
1 cc of Depomedrol 80

Placebo Comparator: 2
4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
Drug: Lidocaine, Marcaine
4 cc of each local anesthetic

Primary Outcome Measures :
  1. WOMAC hip score [ Time Frame: 2 weeks, 6 weeks, 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   17 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients with tenderness at the greater trochanter

Exclusion Criteria:

  • Subjects < 17 years of age
  • Subjects with previous surgery to the greater trochanter
  • Subjects allergic to Lidocaine, Marcaine, or Depomedrol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00863889

Layout table for location information
United States, Georgia
Dr. Tom Bradbury
Atlanta, Georgia, United States, 30306
Sponsors and Collaborators
Emory University
Layout table for investigator information
Principal Investigator: Tom Bradbury, MD Emory University
Additional Information:
Layout table for additonal information
Responsible Party: Thomas L Bradbury, MD, Residency Program Director, Emory University Identifier: NCT00863889    
Other Study ID Numbers: IRB00010776
First Posted: March 18, 2009    Key Record Dates
Last Update Posted: September 23, 2013
Last Verified: September 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Autonomic Agents
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists